Twist Bioscience Corp

Listed Company

TWSTCIK 0001581280NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Sep 30

Period

FY 2025

Revenue

—

Net Income

$-77.70M

Total Assets

$641.86M

Equity

$472.96M

Shares Out

62.27M

Op. Cash Flow

$-47.63M

TWST$93.86+161.96% · past yearDBEQ Basic

Daily closing prices

Business

Twist Bioscience Corporation develops and commercializes a proprietary silicon-based DNA synthesis platform that manufactures synthetic DNA, RNA, and proteins at scale. The company sells synthetic genes, oligonucleotide pools, next-generation sequencing tools, and synthetic controls to researchers and diagnostics companies, alongside biopharma discovery services including antibody optimization and development. Products serve healthcare, chemicals/materials, food/agriculture, and academic research sectors globally through direct sales, e-commerce, and partnerships with over 3,800 customers.

Summary from 10-K filed 2025-11-17

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenues	377	313	245	204	132
Cost of revenues	186	180	155	119	81
Research and development expenses	80	91	107	120	69
Selling, general and administrative expenses	247	218	190	213	136
Restructuring and other costs	0	0	9	0	0
Change in fair value of contingent considerations and holdbacks	0	0	−6	−14	−534,000
Impairment of long-lived assets	0	45	7	0	—
Total costs and expenses	513	534	462	438	285
Loss from operations	−136	−221	−217	−235	−153
Gain on sale of business	49	0	0	—	—
Interest income	11	15	14	3	435,000
Other income (expense), net	−903,000	−3	−672,000	−1	−1
Loss before income taxes	−77	−208	−203	−228	−154
Income tax expense	−700,000	−600,000	−1	10	2
Net loss attributable to common stockholders	−78	−209	−205	−218	−152
Change in unrealized gain (loss) on investments	−50,000	203,000	2	−2	−14,000
Foreign currency translation adjustment	−55,000	31,000	−423,000	−795,000	473,000
Comprehensive loss	−78	−208	−204	−220	−152
Net loss per share attributable to common stockholdersbasic (in dollars per share)	−1.3	−3.6	−3.6	−4.04	−3.15
Net loss per share attributable to common stockholdersdiluted (in dollars per share)	−1.3	−3.6	−3.6	−4.04	−3.15
Weighted average shares used in computing net loss per share attributable to common stockholdersbasic (in shares)	60	58	57	54	48
Weighted average shares used in computing net loss per share attributable to common stockholdersdiluted (in shares)	60	58	57	54	48

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and cash equivalents	183	226	286	379	466
Short-term investments	49	50	50	126	12
Accounts receivable, net	57	35	44	40	29
Inventories	28	24	32	39	32
Prepaid expenses and other current assets	15	11	12	12	8
Total current assets	333	347	424	596	546
Property and equipment, net	102	103	132	139	44
Operating lease right-of-use assets	49	59	72	75	62
Investment in equity securities	54	2	—	—	—
Goodwill	82	86	86	86	22
Intangible assets, net	13	14	54	60	18
Restricted cash, non-current	2	3	3	2	2
Other non-current assets	5	2	6	3	8
Total assets	642	614	776	961	702
Accounts payable	11	2	14	20	15
Accrued expenses	23	15	11	10	6
Accrued compensation	31	34	26	27	22
Current portion of operating lease liability	14	15	15	14	8
Other current liabilities	12	6	8	20	10
Total current liabilities	91	71	73	91	63
Operating lease liability, net of current portion	62	70	79	81	53
Liability related to the sale of future revenue	15	0	—	—	—
Other non-current liabilities	747,000	407,000	475,000	60,000	5
Total liabilities	169	142	153	172	121
Commitments and contingencies	—	—	—	—	—
Common stock, $0.00001 par value 200,000 and 100,000 shares authorized at September 30, 2025 and 2024, respectively; 60,631 and 58,877 shares issued and outstanding at September 30, 2025 and 2024, respectively	0	0	0	0	0
Additional paid-in capital	1,793	1,715	1,657	1,620	1,191
Accumulated other comprehensive loss	−627,000	−522,000	−756,000	−2	546,000
Accumulated deficit	−1,320	−1,242	−1,033	−828	−611
Total stockholders equity	473	473	623	789	581
Total liabilities and stockholders equity	642	614	776	961	702

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Depreciation and amortization expense	25	31	29	17	10
Impairment of long-lived assets	0	45	7	0	0
Non-cash lease expense, net of tenant improvement allowance	−20,000	940,000	3	20	2
Stock-based compensation expense	64	51	30	80	37
Change in fair value of contingent considerations and holdbacks	0	0	−6	—	—
Other non-cash adjustments	2	994,000	120,000	—	—
Accounts receivable, net	−22	8	−4	−10	−2
Inventories	−4	8	7	−8	−19
Prepaid expenses and other current assets	−4	382,000	−4	−3	−2
Other non-current assets	−2	431,000	1	7	−5
Accounts payable	9	−12	−3	7	9
Accrued expenses	6	4	3	2	3
Accrued compensation	−2	8	−1	5	7
Other liabilities	7	−2	−108,000	−7	−28,000
Net cash used in operating activities	−48	−64	−142	−124	−112
Purchases of property and equipment	−28	−5	−28	−102	−27
Purchases of investments	−49	−52	−76	−218	−59
Proceeds from maturity of investments	50	54	155	100	242
Proceeds from sale of business	3	0	0	—	—
Net cash provided by (used in) investing activities	−25	−3	51	−233	156
Proceeds from exercise of stock options	9	7	1	6	15
Proceeds from the issuance of liability related to sale of future revenue	15	0	0	—	—
Proceeds from issuance under employee stock purchase plan	4	4	4	4	5
Repurchases of common stock for income tax withholding	−16,000	−4	−4	−8	−11
Net cash provided by financing activities	29	7	911,000	271	329
Effect of exchange rates on cash, cash equivalents and restricted cash	143,000	126,000	−27,000	−319,000	20,000
Net increase (decrease) in cash, cash equivalents and restricted cash	−44	−60	−91	−87	373
Income taxes paid, net of refunds	683,000	344,000	420,000	246,000	101,000
Property and equipment additions included in accrued expenses and accounts payable	2	92,000	772,000	6	—
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	0	0	7	21	34
Issuance of common stock in connection with the business acquisition	0	0	6	77	27
Tenant improvement allowance capitalized in property and equipment	0	3	0	0	—
Equity securities received as consideration for sale of business	54	0	0	—	—
Promissory note receivable received as consideration for sale of business	2	0	0	—	—
Conversion of convertible notes	0	0	4	0	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Twist Bioscience Corp's CIK number?

Twist Bioscience Corp's SEC CIK number is 0001581280 (1581280). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Twist Bioscience Corp's SEC filings?

All of Twist Bioscience Corp's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Twist Bioscience Corp last report earnings?

Twist Bioscience Corp (TWST) most recently filed an earnings 8-K with the SEC on May 4, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001581280-26-000037). This is Twist Bioscience Corp's most recent earnings filing of record — not a forecast of its next earnings date.

What is Twist Bioscience Corp's most recent earnings 8-K?

Twist Bioscience Corp's latest earnings 8-K (Item 2.02) was filed May 4, 2026 under accession 0001581280-26-000037. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Twist Bioscience Corp's latest earnings 8-K →
Look up any company's CIK number →